Ionis Pharmaceuticals Price Target Maintained With a $70.00/Share by RBC Capital
Ionis Pharmaceuticals Analyst Ratings
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
Ionis Pharmaceuticals (IONS) Receives a Buy From RBC Capital
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $68
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Jefferies Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)
Leerink Partners Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $56
Ionis Pharmaceuticals: A Buy Rating With a Lowered Price Target Amidst Strong Growth Prospects
Ionis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $55
Ionis Pharmaceuticals Price Target Raised to $51.00/Share From $45.00 by Barclays
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $68
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $75
Ionis Pharmaceuticals (IONS) Receives a Buy From RBC Capital
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals: Hold Rating Amid Pipeline Potential and Strategic Challenges